Is BICYCLE THERAPEUTICS PLC (BCYC) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 2.6% / 30% | 243.8% / 30% | 9.9% / 30% | 97.19% / 5% | ✗ NOT HALAL |
| DJIM | 2.6% / 33% | 243.8% / 33% | 9.9% / 33% | 97.19% / 5% | ✗ NOT HALAL |
| MSCI | 1.0% / 33% | 91.9% / 33% | 3.7% / 33% | 97.19% / 5% | ✗ NOT HALAL |
| S&P | 2.6% / 33% | 243.8% / 33% | 9.9% / 33% | 97.19% / 5% | ✗ NOT HALAL |
| FTSE | 1.0% / 33% | 91.9% / 33% | 3.7% / 50% | 97.19% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | -215.6% | |
| Operating Margin | -42.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -31.2% | |
| Return on Assets (ROA) | -18.1% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$250M |
| Free Cash Flow | -$252M |
| Total Debt | $17M |
| Debt-to-Equity | 2.8 |
| Current Ratio | 12.0 |
| Total Assets | $718M |
Price & Trading
| Last Close | $4.50 |
| 50-Day MA | $5.60 |
| 200-Day MA | $6.97 |
| Avg Volume | 369K |
| Beta | 1.6 |
|
52-Week Range
$4.24
| |
About BICYCLE THERAPEUTICS PLC (BCYC)
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle tumor-targeted immune cell agonist molecule, which is in phase I/II targeting nectin-4 and agonizing CD137; and BT1702, a theranostic BRC molecule targeting MT1-MMP for which IND-enabling activities are ongoing. In addition, it develops Novel CNS targets, which is in preclinical trial targeting CNS disease; Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease; and programs that are in preclinical trial targeting radiopharmaceutical. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Ionis Pharmaceuticals, Inc.; Genentech, Inc; and AstraZeneca AB. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is BICYCLE THERAPEUTICS PLC (BCYC) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), BICYCLE THERAPEUTICS PLC is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is BICYCLE THERAPEUTICS PLC's debt ratio?
BICYCLE THERAPEUTICS PLC's debt ratio is 2.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are BICYCLE THERAPEUTICS PLC's key financial metrics?
BICYCLE THERAPEUTICS PLC has a market capitalization of $300M, and revenue of $73M. Return on equity stands at -31.2%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.